Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Eosinophilic Gastritis
NCT03678545Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- May 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic gastritis (EG) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Relative Change of Peak Eosinophil Counts in the Stomach at 12 weeks. Started May 2021; status: completed.
02
Drugs
03
Conditions
eosinophilic gastritis (EG)
Beyond the preview
Go deeper on NCT03678545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678545.